Which drugs are commonly used for the treatment of chronic HepB?

The treatment of chronic Hepatitis B (HepB) primarily focuses on antiviral therapies that target the virus and help to suppress its replication, thereby reducing liver inflammation and preventing progression to cirrhosis or hepatocellular carcinoma. Adefovir and Lamivudine are two nucleoside analogs that have been effectively used in the management of chronic HepB.

Adefovir is a nucleotide reverse transcriptase inhibitor that inhibits the activity of the Hepatitis B virus polymerase, leading to a reduction in viral load. Lamivudine, also a nucleoside reverse transcriptase inhibitor, works similarly to reduce viral replication. These drugs have been shown to improve liver function and reduce the risk of complications associated with chronic HepB.

Other choices listed do not align with the standard treatment regimens for chronic HepB. Ribavirin and Interferons are typically used for Hepatitis C treatment, while Octreotide and sclerotherapy are more relevant to managing complications from portal hypertension, not directly treating HepB. Alkaline phosphatase inhibitors are not specifically indicated in the direct treatment of Hepatitis B. Thus, Adefovir and Lamivudine are indeed the appropriate and commonly used antiviral medications for managing chronic Hepatitis